Id |
Subject |
Object |
Predicate |
Lexical cue |
T548 |
0-168 |
Sentence |
denotes |
Clinical research by Wen Long et al. randomly divided 60 severe COVID-19 patients into routine treatment (n = 20), XBJI 50 ml (n = 20), and XBJI 100 ml (n = 20) groups. |
T549 |
169-341 |
Sentence |
denotes |
On the basis of conventional treatment, XBJI (50 ml) was injected twice a day for 7 days in the XBJI 50 ml group, or 100 ml twice a day for 7 days in the XBJI 100 ml group. |
T550 |
342-478 |
Sentence |
denotes |
After treatment, the white blood cell count (WBC) and lymphocyte count (LYM) of the three groups increased, while CRP and ESR decreased. |
T551 |
479-609 |
Sentence |
denotes |
Compared with the routine treatment group, the WBC count in the XBJI 100 ml group after treatment significantly increased (×109/L: |
T552 |
610-752 |
Sentence |
denotes |
7.12 ± 0.55 vs. 5.67 ± 0.51, p < 0.05), and the levels of CRP and ESR in the XBJI 50 ml and 100 ml groups significantly decreased [CRP (mg/L): |
T553 |
753-803 |
Sentence |
denotes |
32.3 ± 4.6, 28.0 ± 6.2 vs. 37.3 ± 5.9; ESR (mm/h): |
T554 |
804-857 |
Sentence |
denotes |
45.9 ± 5.7, 40.5 ± 7.4 vs. 55.3 ± 6.6, all p < 0.05]. |
T555 |
858-1008 |
Sentence |
denotes |
Compared with the XBJI 50 ml group, the increase of WBC, and the decrease of CRP and ESR were more significant in the XBJI 100 ml group [WBC (×109/L): |
T556 |
1009-1049 |
Sentence |
denotes |
7.12 ± 0.55 vs. 5.82 ± 0.49; CRP (mg/L): |
T557 |
1050-1088 |
Sentence |
denotes |
28.0 ± 6.2 vs. 32.3 ± 4.6; ESR (mm/h): |
T558 |
1089-1130 |
Sentence |
denotes |
40.5 ± 7.4 vs. 45.9 ± 5.7, all p < 0.05]. |
T559 |
1131-1177 |
Sentence |
denotes |
The APACHE II score of three groups decreased. |
T560 |
1178-1377 |
Sentence |
denotes |
In the XBJI 100 ml group, the APACHE II score after treatment was significantly lower than those in the routine treatment and XBJI 50 ml groups (12.3 ± 1.5 vs. 16.5 ± 1.6, 15.9 ± 1.4, both p < 0.05). |
T561 |
1378-1634 |
Sentence |
denotes |
After treatment, the 2019-nCoV nucleic acid test in the three groups partly turned negative: nine cases in the routine treatment group, eight cases in the XBJI 50 ml group and nine cases in the XBJI 100 ml group, with no significant differences (p > 0.05). |
T562 |
1635-1712 |
Sentence |
denotes |
The conditions of patients in the three groups were improved after treatment. |
T563 |
1713-1936 |
Sentence |
denotes |
Eight cases in the routine treatment group were transformed into common type and one case into critical type; nine cases and 12 cases in the XBJI 50 ml and 100 ml groups, respectively, were transformed into the common type. |
T564 |
1937-2063 |
Sentence |
denotes |
Patients in the XBJI 100 ml group improved more obviously than in the XBJI 50 ml and routine treatment groups (both p < 0.05). |
T565 |
2064-2193 |
Sentence |
denotes |
The XBJI injection can effectively improve the inflammatory markers and prognosis of severe COVID-19 patients (Wen et al., 2020). |